Mahmoud Gaballa, MD, Myeloma Specialist in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, shared on X:
“Our work on bispecifics in plasma cell leukemia is now published. Talquetamab showed markedly better outcomes than BCMA bispecifics in patients with active PCL (≥5% circulating PCs), including those who were BCMA-naive.
With virtually no prospective trial data in this space, this striking signal may help inform treatment choice.”
Title: GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia
Authors: Mahmoud R. Gaballa, Kelley Julian, Aimaz Afrough, Doris K. Hansen, Utkarsh Goel, Andre De Menezes Silva Corraes, Danai Dima, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Lindsay Fogel, Shahzad Raza, Rahul Banerjee, Saurabh S. Zanwar, Oren Pasvolsky, Aishwarya Sannareddy, Azra Borogovac, James Davis, Kimberly Green, Noa Biran, Eli Zolotov, Megan Herr, Leyla Shune, Evguenia Ouchveridze, Shaun DeJarnette, Shebli Atrash, Christopher Ferreri, Tiffany Richards, Muhammad Bilal Abid, Susan Bal, Hossam M. Ali, Jing Christine Ye, Shambavi Richard, Gurbakhash Kaur, Kenneth Shain, Omar Castaneda-Puglianini, Ken Harada, Gabriel De Avila, Adriana Rossi, Hamza Hassan, Larry D. Anderson, Peter M. Voorhees, Jack Khouri, Surbhi Sidana, Andrew J. Portuguese, Murali Janakiram, Hans C. Lee, Yi Lin, Ariel Grajales-Cruz, Krina K. Patel, Douglas W. Sborov.
Other articles about BCMA on OncoDaily.